Specialty chemical and ingredient distributor IMCD Group has acquired 100% of Trichem Healthcare's shares.
This is the latest in a streak of recent acquisitions the company has made in the chemical sector.
Through the acquisition of Trichem Healthcare, IMCD will gain access to the company's portfolio of active pharmaceutical ingredients (APIs), pharmaceutical intermediates and formulation solutions.
Trichem also provides regulatory assistance to its customers serving the Indian pharmaceutical market, expanding IMCD's service portfolio in the key region.
Operating across India and the Middle East, Trichem generated a revenue of INR 1.7 billion (ca. EUR 18 million) for the financial year ended 31 March 2025 — of which 33% came from commission income.
"With India being a major supplier of the world’s generic drugs, this acquisition further enhances our portfolio, in particular with active pharmaceutical ingredients, and reinforces our position in the region’s life-sciences industry," said Narendra Varde, Managing Director of IMCD India.
"Additionally, we are excited to welcome Trichem’s talented team, whose deep market expertise and strong industry relationships will be invaluable to IMCD."
Chetan Jain, Founder and Promoter of Trichem Group, added: "IMCD and Trichem share a common vision, strong entrepreneurial spirit, and commitment to building lasting partnerships."
"I am extremely proud of Trichem’s achievements over the past 27 years. Going forward with IMCD’s global presence, and our strong global principal partnerships, I am confident that this business will deliver immense value to our stakeholders.”
